论文部分内容阅读
咳嗽变异性哮喘(cough variant asthma,CVA)是一种特殊类型的哮喘,主要是呼吸道的慢性变态反应性炎症及呼吸道的高反应性。有学者认为CVA是典型哮喘的前期状态[1],需积极治疗。目前白三烯受体拮抗剂作为一类重要的新的抗气喘治疗药已广泛用于临床,其在治疗CVA中的作用日益受到关注。2010年6月至2011年6月我们应用孟鲁司特钠治疗CVA33例,疗效满意,报告如下。1资料与方法1.1临床资料:33例CVA患者,男性13例,女性20例,平
Cough Variant asthma (CVA) is a specific type of asthma, primarily chronic allergic airway inflammation and airway hyperresponsiveness. Some scholars believe that CVA is a typical asthma in the pre-state [1], need active treatment. At present, leukotriene receptor antagonists have been widely used clinically as an important new class of anti-asthmatic therapeutic agents, and their role in the treatment of CVA is gaining more and more attention. June 2010 to June 2011 we use montelukast sodium in the treatment of 33 cases of CVA, with satisfactory results, the report is as follows. 1 Materials and Methods 1.1 Clinical data: 33 patients with CVA, 13 males and 20 females, flat